Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Lacombe

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trialMartin J B Taphoorn, Martin J van den Bent, Murielle E L Mauer, et al.
Journal of Cancer Policy|January 9, 2026
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines ForumDenis Lacombe, Fábio Cardoso Borges, Ana E Amariutei, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2023
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of CancerRobbe Saesen, Mieke Van Hemelrijck, Jan Bogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Improving cancer outcomes through international collaboration in academic cancer treatment trialsEdward L Trimble, Jeffrey S Abrams, Ralph M Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041)Hanneke W M van Laarhoven, Walter Fiedler, Ingrid M E Desar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.
The New England Journal of Medicine|March 11, 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaRoger Stupp, Warren P Mason, Martin J van den Bent, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2019
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncologyRoberto Salgado, David B Solit, David L Rimm, et al.
Neuro-Oncology|February 20, 2009
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951Mathilde C M Kouwenhoven, Thierry Gorlia, Johan M Kros, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trialMartin J B Taphoorn, Martin J van den Bent, Murielle E L Mauer, et al.
Journal of Cancer Policy|January 9, 2026
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines ForumDenis Lacombe, Fábio Cardoso Borges, Ana E Amariutei, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2023
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of CancerRobbe Saesen, Mieke Van Hemelrijck, Jan Bogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Improving cancer outcomes through international collaboration in academic cancer treatment trialsEdward L Trimble, Jeffrey S Abrams, Ralph M Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041)Hanneke W M van Laarhoven, Walter Fiedler, Ingrid M E Desar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.
The New England Journal of Medicine|March 11, 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaRoger Stupp, Warren P Mason, Martin J van den Bent, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2019
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncologyRoberto Salgado, David B Solit, David L Rimm, et al.
Neuro-Oncology|February 20, 2009
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951Mathilde C M Kouwenhoven, Thierry Gorlia, Johan M Kros, et al.
Pageof 12